Hanoi High Tech and Digestive Center at the St. Paul Hospital in Vietnam launches its thermal oncology program with the assistance of Dr. Mark Hurwitz. In the photo above, Dr. Hurwitz is explaining the functions of the thermal mapping probe of the newly installed BSD-2000 3D deep regional hyperthermia system.
Saint Paul General Hospital opened the Digestive Center in 2017, specializing in endoscopic surgery and the treatment of digestive disease including stomach and pelvic cancers. Built following European standards, it is the country’s leading endoscopic surgery facility.
Dr. Hurwitz was invited to lecture on hyperthermia best practices and share his vast knowledge and experiences in the field of thermal oncology and its role in cancer treatment.
Dr. Hurwitz is a globally known thermal oncologist and radiation oncologist. He is currently Vice-Chair for Quality, Safety & Performance Excellence, and Director of Thermal Oncology, Department of Radiation Oncology, at Jefferson Health, Sidney Kimmel Medical College.
Often a featured lecturer at conferences throughout the U.S., Europe, and Asia, his hands-on clinical knowledge of both deep regional and superficial thermal therapy prepares new sites, like St. Paul, to become leaders in this cancer treatment technology.
A special thanks to Pyrexar Medical Vietnam distributor Thai Thinh Medical for sponsoring this event.
Pyrexar Medical exhibited at the PTCOG-NA (Particle Therapy Cooperative Group - North America) held at the Miami Cancer Institute, part of Baptist Health South Florida.
The conference organizers invited Dr. Zeljko Vujaskovic, Director of the Division of Translational Radiation Sciences, University of Maryland School of Medicine, to be a featured speaker at the event. Dr. Vujaskovic presented "Hyperthermia and Protons: Is This the Safe Way to Get the 'Carbon Effect'?" which included some clinical results from the dual therapy. Dr. Vujaskovic and his team at the UMMC have been treating patients with combined hyperthermia and proton beam since the center opened in 2015. The hospital treats patients with the BSD-500 Superficial/Interstitial and the BSD-2000 Deep Regional Hyperthermia System along with protons with great success. His colleague, Dr. J.D. Snider, presented "Concurrent Pencil Beam Scanning Proton Therapy and Hyperthermia: Growing Experience with Promising Results."
(L to R) Dr. Gerhard Sennewald, Dr. Sennewald Medizintechnik; Mark Falkowski, CEO and Mark Kidd, VP Sales and Business Development; Pyrexar Medical
Adding hyperthermia to proton therapy is not new. A BSD-2000 Deep Regional Hyperthermia System located at Kantonsspital Aarau, Switzerland, has established protocols for the combined treatment with excellent outcomes. But the hyperthermia suite and the proton center are a 30-minute drive apart. Therapeutic results can undoubtedly be achieved within the dual therapies recommended target window, but for obvious reasons, this can be a deterrent in best practice and clinical testing. Now with the world's first proton therapy and hyperthermia in the same center (See Hyperthermia + Proton Beam, Now in the US), there are more significant opportunities for clinical research.
There have been a lot of firsts at the Maryland Proton Center. First Proton Center in the region; First center to offer both Hyperthermia + Protons at the same facility, and now they are experiencing another First by treating their 2000th patient!
In their press release, the University states that "just three years after opening its doors, the Maryland Proton Treatment Center (MPTC) has reached a major milestone by treating its 2,000th patient. MPTC is the first proton treatment center to open in the District/Maryland/Virginia region. It is also the only treatment center in the world that offers both proton and thermal therapies in one facility". See the complete press release.
A key figure in the success of the thermal oncology department, Dr. Zeljko Vujaskovic, not only advocates for patients under his care; but continues to share his knowledge, research, and advancements in thermal oncology as he travels the globe as a featured speaker at medical conferences. For Pyrexar Medical, it is a privilege to be associated with such a distinguished group of professionals, researchers, and practitioners of thermal oncology.
Take a Virtual Tour of the BSD-2000
Take a virtual visit to the Thermal Oncology department at the University of Maryland and the BSD-2000 Deep Regional Hyperthermia System. [Note: Hold down the mouse key to move the camera, click to move around the room and use the mouse wheel to zoom
The course drew an international crowd, including physicians from South Korea, Poland, and Japan, as well as prominent cancer centers here in the U.S. From the feedback we received, and this was a five-star educational program, valuable to any member of a thermal oncology team. Topics covered all aspects of practice management, patient treatment, physics, and workflow. Practice managers shared how adding thermal oncology to their services increased overall service revenue by over 19%. This information is essential for centers that would like to add hyperthermia systems but require cost justification to receive purchase approval.
Based on the higher than expected turnout and the response from the participants, we hope this to be offered again in 2020.
Pyrexar Medical will be an exhibiting sponsor of the PTCOG-NA (Particle Therapy Co-Operative Group - North America) in Miami, Florida, October 14-16, our first participation in this annual event. Pyrexar's interest in proton therapy focused after reading a 2014 article published in the International Journal of Hyperthermia by Prof. Dr. Niloy Datta exploring proton therapy and hyperthermia.
Since then, Pyrexar placed a BSD-2000 Deep Regional Hyperthermia System at the University of Maryland Proton Center. The first installation in the world to offer both a proton therapy system and hyperthermia system under the same roof. This installation, along with further clinical study, will move us closer to understanding the relationship of protons combined with focused heating.
For more information on attending the upcoming PTCOG-NA conference, follow the link.
In the last few weeks, Pyrexar products were presented at conferences in Warsaw, Poland; Miami, Florida; Barcelona, Spain; and Münster, Germany. So thankful for our global partners' efforts to educate oncologists and physicists on the benefits of hyperthermia in the treatment of cancer. We wanted to share a few images of these events with you.
Pyrexar's first engagement at the ABS (American Brachytherapy Society). Our goal is to demonstrate that adding hyperthermia as an adjunct to brachytherapy boosted the effectiveness of this radiotherapy treatment without interrupting workflow. It was an excellent show, and we will be back next year.
Pyrexar represented by our distribution partner Magna Medic Systems at the XX Congreso SEOR in Santiago de Compostela, Spain.
The Sociedad Española de Oncología Clínica (Spanish Society of Radiation Oncology) is an association of more than 1000 specialists from Spain (including doctors in training) whose work is developed primarily in the treatment of cancer through the use of ionizing radiation. The annual meeting is an excellent opportunity to share ideas and data from around the world.
Earlier this year, Magna Medic placed a BSD-500 Superficial Hyperthermia unit at the Clinica Sagrada Familia in Barcelona, Spain. The facility boasts a 135 bed, 225,000 sqft facility with eight specialty surgical suites to support cardiac surgery, neurosurgery, ophthalmology, general surgery, and traumatology. Clinica Sagrada currently performs over 12,000 surgeries per year.
We are very thankful for the hard work the Magna Medic team has done to bring hyperthermia to Spain.
This is our first time exhibiting at the conference, and we believe we have a compelling solution to offer. HDR (high dose rate) brachytherapy and hyperthermia share some of the same market challenges. The bottom line is that brachytherapy plus hyperthermia improve cancer patient outcomes.
Like hyperthermia, brachytherapy is a sub-specialty that requires a specific skill set to treat patients. And like hyperthermia, brachytherapy is known to produce increased tumor control without an increase in toxicity. Product planning for hyperthermia is very similar, and the system utilizes the existing brachy catheters placed during HDR.
This month the 33rd Annual Meeting of the European Society for Hyperthermic Oncology (ESHO 2019) will be held in Warsaw, Poland, at the Warsaw Plaza Hotel, on May 22 - 24, 2019. The conference invites thermal oncology professionals with extensive clinical and scientific experience to share their expertise in the field.
Pyrexar Medical is represented by our European distribution partner Dr. Sennewald Medizintechnik and Poland distributor HT Systems.
Pyrexar Represented by:
The conference includes over 58 presentations by leading hyperthermia experts. Highlights below:
MR thermometry validation and modeling of a 915 MHz annular phased-array in brain phantoms
A meta-analysis of clinical trials with hyperthermia
Protons and hyperthermia: early clinical results
Building an international forum to boost hyperthermic research
Quality assurance guidelines for hyperthermia
H. Dobsicek Trefna
Quality assurance assessment: are commercial MR-guided deep-pelvic hyperthermia devices ready for a large clinical trial?
QA techniques for radiative deep hyperthermia systems: benefits and limitations of 1D, 2D, and 3D techniques
Gerard van Rhoon
Combined interstitial radiotherapy with interstitial hyperthermia
Thermochemoradiotherapy for locally advanced pancreatic cancers: A pilot study
Radiotherapy in combination with regional Hyperthermia for Salvage Treatment in refractory Childhood Cancer
Pyrexar Medical would like to congratulate Ruediger Wessalowski, MD, and Chris Diederich, Ph.D., for the recent honors awarded them at this year's Society for Thermal Medicine annual conference held in Florida last week.
Dr. Ruediger Wessalowski awarded the prestigious J. Eugene Robinson Award. The J. Eugene Robinson Award is presented each year to an investigator who has made outstanding contributions to hyperthermic oncology. Dr. Wessalowski practices at the Clinic for Pediatric Oncology, Hematology, and Clinical Oncology at the Heinrich-Heine-University (HHU) located in Düsseldorf, Germany. He is honored for his work in pioneering caring and innovative cancer treatment solutions for children and his continuing advancements in hyperthermia best practices. HHU uses the Pyrexar BSD-500, BSD-2000, and the BSD-2000 3D/MR Hyperthermia systems.
Chris Diederich, Ph.D., was honored with the George M. Hahn Award. The George M. Hahn Award is presented every other year to an investigator whose research has contributed in a significant way to new clinical applications in thermal therapy. Professor Diederich is the Director of Clinical Hyperthermia Physics and Thermal Therapy Research at the University of California, San Francisco. The Pyrexar BSD-500 and BSD-2000 hyperthermia systems are in practice at the UCSF Helen Diller Family Comprehensive Cancer Center.
About STM Founded in 1986, the Society of Thermal Medicine is a premier, international scientific forum for fostering interaction and innovation in the study of biological, physical and medical applications of thermal therapy for cancer and other diseases and for facilitating a greater fundamental understanding of the role of temperature in cellular and molecular function.
Dr. Sennewald Medizintechnik, Pyrexar's European distribution partner, has brought together an impressive program of clinicians to talk about hyperthermia's role in the treatment of cancer, at this years ESTRO 38 (European Society for Radiotherapy & Oncology). The luncheon symposium titled "Hyperthermia in the age of personalized oncology" will be held Saturday, April 27th, and is open to all ESTRO attendees (space is limited).
Program outline below:
Daniel Zips, UMC Tübingen, Germany
Hyperthermia as an immune modulator in multimodal tumor therapies - immune biological rationale
Michael Hader, Ph.D., UMC Erlangen, Germany
Integration of Pencil Beam Scanning Proton Therapy and Hyperthermia: The University of Maryland Clinical Experience
Zeljko Vujaskovic MD, University of Maryland, USA
Management of locally recurrent Breast Cancers with local hyperthermia and radiotherapy: A systematic review and meta-analysis
Niloy Datta MD, Canton Hospital Aarau, Switzerland
Neoadjuvant chemotherapy combined with deep regional hyperthermia as the new standard for the treatment of patients with high-risk soft-tissue sarcomas
Lars Lindner MD, UMC Munich Grosshadern, Germany
Hyperthermia and preoperative chemoradiation for organ-preservation in rectal cancer patients
Cihan Gani MD, UMC Tübingen, Germany
Discussion and Summary
Stephan Bodis MD, Canton Hospital Aarau, Switzerland
Founded in 1980, ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organization that fosters the role of Radiation Oncology to improve patients’ care in the multimodality treatment of cancer. ESTRO 38 is held in Milan, Italy, April 26th - 30th, 2019, at the Milan Convention Center.
It is a busy Spring for Pyrexar at the upcoming Conference Events in the US and Europe. These conferences are a gathering of the best in radiation oncology and hyperthermia experts and an excellent resource for those interested in the field of thermal oncology. We will be exhibiting, either directly or via our distribution partners, at the following events
The 36th Annual Meeting of the Society for Thermal Medicine, 33rd Annual Meeting of the European Society for Hyperthermic Oncology, 20th Congress of the Spanish Society of Radiation Oncology, and the 2019 American Brachytherapy Society Annual Meeting will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding radiation oncology and thermal medicine in the context of engineering, physics, materials science, and biology.
It has been four years since we acquired the hyperthermia division from BSD Medical and started Pyrexar Medical. In addition to getting the technology rights to this life-changing technology, we also received a group of great, hardworking people. Pyrexar may be only celebrating year four, but we do this sitting atop four decades of drive, innovation, and the desire to give those that are battling cancer, a higher chance at disease-free survival.
We are looking toward achieving great strides in this next year. With that, we have many people to thank, and that includes you. Thank you to all of our supporters, partners, researchers, physicians, physicists, radiation therapists, nurses, and administrative staff around the world. To those that continue to believe in the bright future of hyperthermia and to those who demand the best outcomes for their patients.